Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.
about
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateThe Clinical Pharmacology of Elotuzumab.Pharmacokinetics of Monoclonal Antibodies.Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
P2860
Q28076147-789D1AA5-9FD6-4018-A1C3-1607A2FA427EQ38639376-CFFBC104-B1F6-4376-968F-BADEEDD231C1Q42118646-8AC4204D-83B2-4BFF-A515-F56CE04FCFC5Q47568807-19E872E2-8D77-4D6E-BB54-CAE57BA85BA3Q47688664-FF0B741C-F798-4C3A-9DE1-DAFA89D87F21Q47865755-9BECCC3C-C688-4A37-A993-1459BC17FF3EQ55409204-755519C5-1506-4EF4-8B7A-DDB8532A46F1
P2860
Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Model-based pharmacokinetic an ...... d/refractory multiple myeloma.
@en
Model-based pharmacokinetic an ...... d/refractory multiple myeloma.
@nl
type
label
Model-based pharmacokinetic an ...... d/refractory multiple myeloma.
@en
Model-based pharmacokinetic an ...... d/refractory multiple myeloma.
@nl
prefLabel
Model-based pharmacokinetic an ...... d/refractory multiple myeloma.
@en
Model-based pharmacokinetic an ...... d/refractory multiple myeloma.
@nl
P2093
P2860
P1476
Model-based pharmacokinetic an ...... d/refractory multiple myeloma.
@en
P2093
Akintunde Bello
Chaitali Passey
Leonid Gibiansky
Manish Gupta
P2860
P2888
P304
P356
10.1007/S10928-016-9469-X
P577
2016-03-18T00:00:00Z